---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-008575"
form_type: "8-K"
ticker: "HIND"
cik: "0001427570"
company_name: "Vyome Holdings, Inc"
filed_at: "2026-01-28T23:59:59+00:00"
generated_at: "2026-05-16T06:57:26.395780+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Vyome VT-1953 valuation: $455M rNPV, potential $1.086B after Phase 3

## Summary
- Independent report values VT-1953 at $455M rNPV in H1 2026, growing to $1.086B post-Phase 3 in H1 2028.
- No FDA-approved therapies for malignant fungating wounds; 56.5% probability of approval assumed.
- Peak net sales imply $2.2B TAM in 2026, $2.8B by 2040; 30% market share modeled.
- Pricing $20/gram ($9,125/month); Phase 3 starts Q3 2026, NDA and launch targeted Q4 2028.
- Development costs to 2028 estimated at $10M; potential partners include BMS and Pierre Fabre.

## SEC filing metadata
- accession: 0001213900-26-008575
- form_type: 8-K
- ticker: HIND
- cik: 0001427570
- company_name: Vyome Holdings, Inc
- filed_at: 2026-01-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427570/000121390026008575/0001213900-26-008575-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427570/000121390026008575/ea0274367-8k_vyome.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-008575
- JSON: https://secwatch.observer/filing/0001213900-26-008575.json
- Plain text: https://secwatch.observer/filing/0001213900-26-008575.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.